McKinsey Settles Opioid Crisis Claims for $78 Million

McKinsey and Co. has agreed to pay $78 million to settle claims that its work with drug companies helped fuel the opioid addiction crisis in the US. The settlement includes the establishment of a fund to reimburse insurers and others for some or all of their prescription opioid costs.

Consulting firm McKinsey and Co. has agreed to pay $78 million to settle claims from insurers and healthcare funds that its work with drug companies contributed to the opioid addiction crisis. The settlement, disclosed in documents filed in a federal court in San Francisco, awaits judicial approval.

Reimbursing Opioid Costs

Under the settlement, McKinsey will establish a fund to reimburse insurers, private benefit plans, and others for a portion or all of their prescription opioid costs. Insurers alleged that McKinsey collaborated with Purdue Pharma, the manufacturer of OxyContin, to develop and implement aggressive marketing and sales strategies to overcome doctors' reservations about the highly addictive drugs.

As a result, insurers claim they were compelled to cover prescription opioids instead of safer, non-addictive, and more affordable alternatives, including over-the-counter pain relievers. Additionally, they incurred expenses for subsequent opioid addiction treatment.

Opioid Crisis and McKinsey's Involvement

According to the US Centers for Disease Control, nearly 280,000 individuals in the United States died from prescription opioid overdoses between 1999 and 2021. Insurers contend that McKinsey continued its collaboration with Purdue Pharma even after the severity of the opioid crisis became evident.

The settlement represents the latest development in a protracted effort to hold McKinsey accountable for its role in the opioid epidemic. In February 2021, the company agreed to pay nearly $600 million to US states, the District of Columbia, and five US territories. In September, McKinsey announced a separate $230 million settlement agreement with school districts and local governments.

McKinsey's Response

When contacted for comment, McKinsey referred to a statement released in September. The company maintained that its past work was lawful and denied any allegations to the contrary. However, it reached a settlement to avoid protracted litigation. McKinsey also stated that it ceased advising clients on any opioid-related business in 2019.

The settlement underscores the ongoing efforts to address the devastating impact of the opioid crisis and hold accountable those deemed responsible for contributing to it.